{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T22:39:48Z","timestamp":1788993588558,"version":"build-2803163510"},"reference-count":48,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T00:00:00Z","timestamp":1741651200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["NRF-2021R1C1C1012397"],"award-info":[{"award-number":["NRF-2021R1C1C1012397"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["RS-2020-KH088690"],"award-info":[{"award-number":["RS-2020-KH088690"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Korea Health Industry Development Institute (KHIDI)","award":["NRF-2021R1C1C1012397"],"award-info":[{"award-number":["NRF-2021R1C1C1012397"]}]},{"name":"Korea Health Industry Development Institute (KHIDI)","award":["RS-2020-KH088690"],"award-info":[{"award-number":["RS-2020-KH088690"]}]},{"name":"Chungnam National University","award":["NRF-2021R1C1C1012397"],"award-info":[{"award-number":["NRF-2021R1C1C1012397"]}]},{"name":"Chungnam National University","award":["RS-2020-KH088690"],"award-info":[{"award-number":["RS-2020-KH088690"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Antithymocytic globulin (ATG) and post-transplant cyclophosphamide (PTCy) are frequently used regimens for graft-versus-host disease (GVHD) prophylaxis. However, there is a lack of data about the difference in regulatory T-cell (Treg) subpopulations between these two regimens. Peripheral blood samples were collected on day +21 following allogeneic hematopoietic stem cell transplantation (Allo-HSCT), and the Treg subpopulations were analyzed using flow cytometry. The Treg populations were categorized into three distinct subgroups: na\u00efve, effector, and non-suppressive. And we compared overall survival (OS), the cumulative incidence of acute and chronic GVHD, and the relapse rate between the ATG and PTCy groups. We enrolled 45 patients (28 in ATG, 17 in PTCy) in total. In the ATG group, 16 and 12 patients underwent human leukocyte antigen (HLA) matched-sibling donor and unrelated donor HSCT, respectively. In the PTCy group, 12 patients underwent haplo-identical HSCT, and 5 patients underwent HLA-matched unrelated donor HSCT. The cumulative incidence of Grade 2\u20134 acute GVHD was 18.3% in the ATG group compared to 38.1% in the PTCy group (p = 0.13), while severe chronic GVHD occurred in 19.4% of ATG patients and 41.7% of PTCy patients (p = 0.343). And OS and the relapse rate were not statistically different between the two groups. The conventional CD25+FOXP3+Treg count of CD4 + T cells was higher in the PTCy group than in the ATG group (p = 0.0020). The effector Treg subset was significantly higher in the PTCy group than in the ATG group (p = 0.0412). And the effector Treg cell count had an inverse correlation with the severity of acute GVHD (p = 0.0007). Effector Tregs may be used as a biomarker to predict the severity of acute GVHD after allo-HSCT.<\/jats:p>","DOI":"10.3390\/ijms26062521","type":"journal-article","created":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T16:39:03Z","timestamp":1741711143000},"page":"2521","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Comparison of Regulatory T-Cell Subpopulations in Antithymocytic Globulin Versus Post-Transplant Cyclophosphamide for Preventing Graft-Versus-Host Disease in Allogeneic Hematopoietic Stem Cell Transplantation\u2014A Retrospective Study"],"prefix":"10.3390","volume":"26","author":[{"given":"Bu-Yeon","family":"Heo","sequence":"first","affiliation":[{"name":"Department of Medical Science, College of Medicine, Chungnam National University, Daejeon 35015, Republic of Korea"},{"name":"Brain Korea 21 FOUR Project for Medical Science, College of Medicine, Chungnam National University, Daejeon 35015, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4251-7310","authenticated-orcid":false,"given":"Jeong Suk","family":"Koh","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, College of Medicine, Chungnam National University, Daejeon 34134, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7474-610X","authenticated-orcid":false,"given":"Su-Young","family":"Choi","sequence":"additional","affiliation":[{"name":"Department of Medical Science, College of Medicine, Chungnam National University, Daejeon 35015, Republic of Korea"},{"name":"Brain Korea 21 FOUR Project for Medical Science, College of Medicine, Chungnam National University, Daejeon 35015, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1528-3213","authenticated-orcid":false,"given":"Thi Thuy Duong","family":"Pham","sequence":"additional","affiliation":[{"name":"Department of Medical Science, College of Medicine, Chungnam National University, Daejeon 35015, Republic of Korea"},{"name":"Brain Korea 21 FOUR Project for Medical Science, College of Medicine, Chungnam National University, Daejeon 35015, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang-Woo","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Medical Science, College of Medicine, Chungnam National University, Daejeon 35015, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung-Hyun","family":"Park","sequence":"additional","affiliation":[{"name":"Translational Immunology Institute, College of Medicine, Chungnam National University, Daejeon 35015, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2693-3098","authenticated-orcid":false,"given":"Yunseon","family":"Jang","sequence":"additional","affiliation":[{"name":"Translational Immunology Institute, College of Medicine, Chungnam National University, Daejeon 35015, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myung-Won","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, College of Medicine, Chungnam National University, Daejeon 34134, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seul-Bi","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, College of Medicine, Chungnam National University, Daejeon 34134, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wonhyoung","family":"Seo","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, College of Medicine, Chungnam National University, Daejeon 34134, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8267-4214","authenticated-orcid":false,"given":"Deog-Yeon","family":"Jo","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, College of Medicine, Chungnam National University, Daejeon 34134, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2452-4111","authenticated-orcid":false,"given":"Jaeyul","family":"Kwon","sequence":"additional","affiliation":[{"name":"Department of Medical Science, College of Medicine, Chungnam National University, Daejeon 35015, Republic of Korea"},{"name":"Brain Korea 21 FOUR Project for Medical Science, College of Medicine, Chungnam National University, Daejeon 35015, Republic of Korea"},{"name":"Translational Immunology Institute, College of Medicine, Chungnam National University, Daejeon 35015, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6938-970X","authenticated-orcid":false,"given":"Ik-Chan","family":"Song","sequence":"additional","affiliation":[{"name":"Department of Medical Science, College of Medicine, Chungnam National University, Daejeon 35015, Republic of Korea"},{"name":"Brain Korea 21 FOUR Project for Medical Science, College of Medicine, Chungnam National University, Daejeon 35015, Republic of Korea"},{"name":"Department of Internal Medicine, College of Medicine, Chungnam National University, Daejeon 34134, Republic of Korea"},{"name":"Translational Immunology Institute, College of Medicine, Chungnam National University, Daejeon 35015, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,3,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1056\/NEJMoa1004383","article-title":"Reduced Mortality after Allogeneic Hematopoietic-Cell Transplantation","volume":"363","author":"Gooley","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e157","DOI":"10.1016\/S2352-3026(19)30256-X","article-title":"Prophylaxis and Management of Graft Versus Host Disease after Stem-Cell Transplantation for Haematological Malignancies: Updated Consensus Recommendations of the European Society for Blood and Marrow Transplantation","volume":"7","author":"Penack","year":"2020","journal-title":"Lancet Haematol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1056\/NEJMoa1506002","article-title":"Antilymphocyte Globulin for Prevention of Chronic Graft-versus-Host Disease","volume":"374","author":"Solano","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1182\/blood.2021015129","article-title":"How I Prevent GVHD in High-Risk Patients: Posttransplant Cyclophosphamide and Beyond","volume":"141","author":"Rimando","year":"2023","journal-title":"Blood"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1038\/sj.leu.2404683","article-title":"Mechanisms of Action of Antithymocyte Globulin: T-Cell Depletion and Beyond","volume":"21","author":"Mohty","year":"2007","journal-title":"Leukemia"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"3993","DOI":"10.1200\/JCO.2017.76.0512","article-title":"Antithymocyte Globulin for Graft-Versus-Host Disease Prophylaxis after Allogeneic Hematopoietic Stem-Cell Transplantation","volume":"35","author":"Mohty","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s12026-009-8139-0","article-title":"High-Dose, Post-Transplantation Cyclophosphamide to Promote Graft-Host Tolerance after Allogeneic Hematopoietic Stem Cell Transplantation","volume":"47","author":"Luznik","year":"2010","journal-title":"Immunol. Res."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1200\/JCO.2012.44.3523","article-title":"T-Cell-Replete HLA-Haploidentical Hematopoietic Transplantation for Hematologic Malignancies Using Post-Transplantation Cyclophosphamide Results in Outcomes Equivalent to Those of Contemporaneous HLA-Matched Related and Unrelated Donor Transplantation","volume":"31","author":"Bashey","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"391","DOI":"10.3324\/haematol.2016.144139","article-title":"Comparable Composite Endpoints After HLA-Matched and HLA-Haploidentical Transplantation with Post-Transplantation Cyclophosphamide","volume":"102","author":"McCurdy","year":"2017","journal-title":"Haematologica"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1038\/s41409-022-01781-9","article-title":"Comparison of HLA-Mismatched Unrelated Donor Transplantation with Post-Transplant Cyclophosphamide versus HLA-Haploidentical Transplantation in Patients with Active Acute Myeloid Leukemia","volume":"57","author":"Baron","year":"2022","journal-title":"Bone Marrow Transplant."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.3324\/haematol.2020.247296","article-title":"Post-Transplant Cyclophosphamide versus Anti-Thymocyte Globulin for Graft-Versus-Host Disease Prevention in Haploidentical Transplantation for Adult Acute Lymphoblastic Leukemia","volume":"106","author":"Nagler","year":"2021","journal-title":"Haematologica"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Ikegawa, S., and Matsuoka, K.I. (2021). Harnessing Treg Homeostasis to Optimize Posttransplant Immunity: Current Concepts and Future Perspectives. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.713358"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1172\/JCI41072","article-title":"Altered Regulatory T Cell Homeostasis in Patients with CD4+ Lymphopenia Following Allogeneic Hematopoietic Stem Cell Transplantation","volume":"120","author":"Matsuoka","year":"2010","journal-title":"J. Clin. Investig."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Meguri, Y., Asano, T., Yoshioka, T., Iwamoto, M., Ikegawa, S., Sugiura, H., Kishi, Y., Nakamura, M., Sando, Y., and Kondo, T. (2022). Responses of Regulatory and Effector T-Cells to Low-Dose Interleukin-2 Differ Depending on the Immune Environment after Allogeneic Stem Cell Transplantation. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.891925"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1158\/1078-0432.CCR-13-3205","article-title":"Ultra low-dose IL-2 for GVHD Prophylaxis After Allogeneic Hematopoietic Stem Cell Transplantation Mediates Expansion of Regulatory T Cells Without Diminishing Antiviral and Antileukemic Activity","volume":"20","author":"Ku","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1007\/s12185-017-2386-y","article-title":"Low-Dose Interleukin-2 as a Modulator of Treg Homeostasis After HSCT: Current Understanding and Future Perspectives","volume":"107","author":"Matsuoka","year":"2018","journal-title":"Int. J. Hematol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1182\/blood-2006-08-044529","article-title":"In Vivo Dynamics of Regulatory T-Cell Trafficking and Survival Predict Effective Strategies to Control Graft-Versus-Host Disease Following Allogeneic Transplantation","volume":"109","author":"Nguyen","year":"2007","journal-title":"Blood"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1182\/blood-2007-07-103895","article-title":"The Impact of Regulatory T Cells on T-Cell Immunity Following Hematopoietic Cell Transplantation","volume":"111","author":"Nguyen","year":"2008","journal-title":"Blood"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1016\/j.ymthe.2022.02.025","article-title":"Adoptive Transfer of Ex Vivo Expanded Regulatory T Cells Improves Immune Cell Engraftment and Therapy-Refractory Chronic GvHD","volume":"30","author":"Kuehl","year":"2022","journal-title":"Mol. Ther."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/ni904","article-title":"Foxp3 Programs the Development and Function of CD4+CD25+ Regulatory T Cells","volume":"4","author":"Fontenot","year":"2003","journal-title":"Nat. Immunol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/j.immuni.2018.04.008","article-title":"Proteomic Analyses of Human Regulatory T Cells Reveal Adaptations in Signaling Pathways that Protect Cellular Identity","volume":"48","author":"Cuadrado","year":"2018","journal-title":"Immunity"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.3346\/jkms.2012.27.9.1009","article-title":"Subpopulations of Regulatory T Cells in Rheumatoid Arthritis, Systemic Lupus Erythematosus, and Behcet\u2019s Disease","volume":"27","author":"Kim","year":"2012","journal-title":"J. Korean Med. Sci."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/s41590-018-0120-4","article-title":"Regulatory T Cells in Autoimmune Disease","volume":"19","author":"Hafler","year":"2018","journal-title":"Nat. Immunol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1146\/annurev-immunol-042718-041717","article-title":"Regulatory T Cells and Human Disease","volume":"38","author":"Sakaguchi","year":"2020","journal-title":"Annu. Rev. Immunol."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Go, E., Yoo, S.J., Choi, S., Sun, P., Jung, M.K., Kwon, S., Heo, B.Y., Kim, Y., Kang, J.G., and Kim, J. (2021). Peripheral Blood from Rheumatoid Arthritis Patients Shows Decreased T(reg) CD25 Expression and Reduced Frequency of Effector T(reg) Subpopulation. Cells, 10.","DOI":"10.3390\/cells10040801"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s44313-024-00049-z","article-title":"Post-Transplant Cyclophosphamide Plus Anti-Thymocyte Globulin Decreased Serum IL-6 Levels When Compared with Post-Transplant Cyclophosphamide Alone After Haploidentical Hematopoietic Stem Cell Transplantation","volume":"60","author":"Koh","year":"2025","journal-title":"Blood Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1016\/j.bbmt.2016.06.010","article-title":"Severe Cytokine-Release Syndrome after T Cell-Replete Peripheral Blood Haploidentical Donor Transplantation Is Associated with Poor Survival and Anti-IL-6 Therapy Is Safe and Well Tolerated","volume":"22","author":"Abboud","year":"2016","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1016\/j.bbmt.2019.06.003","article-title":"Clinical Impacts of Using Serum IL-6 Level as an Indicator of Cytokine Release Syndrome after HLA-Haploidentical Transplantation with Post-Transplantation Cyclophosphamide","volume":"25","author":"Nishimoto","year":"2019","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"155654","DOI":"10.1016\/j.cyto.2021.155654","article-title":"Role of IL-6 in the Commitment of T Cell Subsets","volume":"146","author":"Korn","year":"2021","journal-title":"Cytokine"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.immuni.2013.05.018","article-title":"Stabilization of the Transcription Factor Foxp3 by the Deubiquitinase USP7 Increases Treg-Cell-Suppressive Capacity","volume":"39","author":"Fleskens","year":"2013","journal-title":"Immunity"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/s41591-018-0036-4","article-title":"Monocyte-Derived IL-1 and IL-6 Are Differentially Required for Cytokine-Release Syndrome and Neurotoxicity due to CAR T Cells","volume":"24","author":"Norelli","year":"2018","journal-title":"Nat. Med."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Greco, R., Lorentino, F., Nitti, R., Lupo Stanghellini, M.T., Giglio, F., Clerici, D., Xue, E., Lazzari, L., Piemontese, S., and Mastaglio, S. (2019). Interleukin-6 as Biomarker for Acute GvHD and Survival After Allogeneic Transplant with Post-transplant Cyclophosphamide. Front. Immunol., 10.","DOI":"10.3389\/fimmu.2019.02319"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"401","DOI":"10.3324\/haematol.2016.151779","article-title":"Post-Transplant Cyclophosphamide versus Anti-Thymocyte Globulin as Graft- Versus-Host Disease Prophylaxis in Haploidentical Transplant","volume":"102","author":"Ruggeri","year":"2017","journal-title":"Haematologica"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s00277-021-04399-x","article-title":"Post-transplant Cyclophosphamide Versus Antithymocyte Globulin in Allogeneic Hematopoietic Cell Transplantation: A Meta-Analysis","volume":"100","author":"Gao","year":"2021","journal-title":"Ann. Hematol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1182\/bloodadvances.2020003005","article-title":"Impaired T- and NK-Cell Reconstitution after Haploidentical HCT with Posttransplant Cyclophosphamide","volume":"5","author":"Rambaldi","year":"2021","journal-title":"Blood Adv."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"211ra157","DOI":"10.1126\/scitranslmed.3006960","article-title":"Aldehyde Dehydrogenase Expression Drives Human Regulatory T Cell Resistance to Posttransplantation Cyclophosphamide","volume":"5","author":"Kanakry","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1182\/blood-2013-10-525873","article-title":"Donor CD4+ Foxp3+ Regulatory T Cells Are Necessary for Posttransplantation Cyclophosphamide-Mediated Protection Against GVHD in Mice","volume":"124","author":"Ganguly","year":"2014","journal-title":"Blood"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Heo, B.Y., Lee, M.W., Choi, S., Jung, Y., Pham, T.T.D., Jang, Y., Park, J.H., Kang, S., Koh, J.S., and Jo, D.Y. (2023). Autoimmune Limbic Encephalitis in Patients with Hematologic Malignancies after Haploidentical Hematopoietic Stem Cell Transplantation with Post-Transplant Cyclophosphamide. Cells, 12.","DOI":"10.20944\/preprints202305.0700.v1"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s13045-020-00882-6","article-title":"Post-Transplant Cyclophosphamide After Matched Sibling, Unrelated and Haploidentical Donor Transplants in Patients with Acute Myeloid Leukemia: A Comparative Study of the ALWP EBMT","volume":"13","author":"Sanz","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1038\/s41409-022-01816-1","article-title":"Should Anti-Thymocyte Globulin Be Added in Post-Transplant Cyclophosphamide Based Matched Unrelated Donor Peripheral Blood Stem Cell Transplantation for Acute Myeloid Leukemia? A Study on Behalf of the Acute Leukemia Working Party of the EBMT","volume":"57","author":"Spyridonidis","year":"2022","journal-title":"Bone Marrow Transplant."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"101080","DOI":"10.1016\/j.blre.2023.101080","article-title":"Combining Post-Transplant Cyclophosphamide with Antithymocyte Globulin for Graft-Versus-Host Disease Prophylaxis in Hematological Malignancies","volume":"62","author":"Brissot","year":"2023","journal-title":"Blood Rev."},{"key":"ref_42","first-page":"e531","article-title":"Cytomegalovirus Reactivations in Allogeneic Hematopoietic Stem Cell Transplantation from HLA-Matched and Haploidentical Donors with Post-Transplantation Cyclophosphamide","volume":"30","author":"Henriques","year":"2024","journal-title":"Transpl. Cell Ther."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"3002","DOI":"10.1200\/JCO.2017.72.8428","article-title":"Mobilized Peripheral Blood Stem Cells Versus Unstimulated Bone Marrow As a Graft Source for T-Cell-Replete Haploidentical Donor Transplantation Using Post-Transplant Cyclophosphamide","volume":"35","author":"Bashey","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s13045-018-0586-4","article-title":"Post-Transplant Cyclophosphamide for Graft-Versus-Host Disease Prophylaxis in HLA Matched Sibling or Matched Unrelated Donor Transplant for Patients with Acute Leukemia, on Behalf of ALWP-EBMT","volume":"11","author":"Ruggeri","year":"2018","journal-title":"J. Hematol. Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"e21571","DOI":"10.1097\/MD.0000000000021571","article-title":"A Comparison of Post-Transplantation Cyclophosphamide Versus Antithymocyte-Globulin in Patients with Hematological Malignancies Undergoing HLA-Matched Unrelated Donor Transplantation","volume":"99","author":"Lee","year":"2020","journal-title":"Medicine"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S1470-2045(15)00462-3","article-title":"Pretreatment with Anti-Thymocyte Globulin Versus No Anti-Thymocyte Globulin in Patients with Haematological Malignancies Undergoing Haemopoietic Cell Transplantation from Unrelated Donors: A Randomised, Controlled, Open-Label, Phase 3, Multicentre Trial","volume":"17","author":"Walker","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.bbmt.2015.09.001","article-title":"International, Multicenter Standardization of Acute Graft-versus-Host Disease Clinical Data Collection: A Report from the Mount Sinai Acute GVHD International Consortium","volume":"22","author":"Harris","year":"2016","journal-title":"Biol. Blood Marrow Transpl."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/j.bbmt.2015.02.025","article-title":"Measuring Therapeutic Response in Chronic Graft-Versus-Host Disease. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-Versus-Host Disease: IV. The 2014 Response Criteria Working Group report","volume":"21","author":"Lee","year":"2015","journal-title":"Biol. Blood Marrow Transpl."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/6\/2521\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:50:54Z","timestamp":1760028654000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/6\/2521"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,11]]},"references-count":48,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,3]]}},"alternative-id":["ijms26062521"],"URL":"https:\/\/doi.org\/10.3390\/ijms26062521","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,11]]}}}